- Home
- ADSE vs DNA Comparison
ADSE vs DNA Comparison
Compare ADSE & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADSE | DNA |
|---|---|---|
| Founded | 1980 | 2008 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 577.8M | 562.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ADSE | DNA |
|---|---|---|
| Price | $12.27 | $8.61 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 26.9K | ★ 1.2M |
| Earning Date | 12-23-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $53,275,396.00 | ★ $180,606,000.00 |
| Revenue This Year | $219.58 | N/A |
| Revenue Next Year | N/A | $14.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.89 | $5.00 |
| 52 Week High | $16.35 | $17.58 |
Technical Indicators
Market Signals| Indicator | ADSE | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 67.24 | 38.67 |
| Support Level | $9.76 | $7.36 |
| Resistance Level | $10.68 | $9.38 |
| Average True Range (ATR) | 0.68 | 0.50 |
| MACD | 0.24 | 0.20 |
| Stochastic Oscillator | 89.47 | 61.88 |
Price Performance
Historical ComparisonAbout ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.